Tag: EMA
International Perspectives on NTI Generics: Regulatory Approaches Compared
NTI generics require strict regulatory oversight due to their narrow safety margin. This article compares how the FDA, EMA, Health Canada, and others regulate these high-risk drugs, highlighting differences in bioequivalence standards, approval timelines, and substitution rules.
Dec 19 2025
Global Medication Safety: How the U.S., EU, Canada, and Australia Regulate Drugs Differently
The U.S., EU, Canada, and Australia each have unique drug approval and safety systems. These differences affect which medications are available, how quickly they’re approved, and when they’re pulled from the market - with real consequences for patients worldwide.
Nov 29 2025
